openPR Logo
Press release

Retroperitoneal Liposarcoma Treatment Market - Size, Share, Outlook, and Opportunity Analysis

08-28-2018 02:04 PM CET | Health & Medicine

Press release from: Coherent Market Insights

Retroperitoneal Liposarcoma Treatment Market - Size, Share,

Retroperitoneal liposarcoma (RLS) is a rare, biologically heterogeneous cancer, which occurs in retroperitoneum, lining of the abdominal space that covers the abdominal organs. Retroperitoneal liposarcoma grow continuously and may not get diagnosed until they are very large thus, its prognosis is poor compared to the other subtypes of retroperitoneal sarcomas. The reason for the development of these tumors are still unknown, however, genetic mutation is considered to be one of the factors leading to the generation of these tumors. Incidence of this disease is equal in men and women, with a slight predominance of men. This tumor has no characteristic symptoms and are usually diagnosed during the advanced stage.

Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1861

Furthermore, the effectiveness of radiotherapy or chemotherapy for the treatment of this tumor is not properly defined, as they are massive in size and might involve adjacent visceral organs and critical structures. However, affected population who received adjuvant chemotherapy showed survival benefits and improvement, as compared to patients who underwent surgery alone. In the case of surgeries, sometimes, preoperative radiation is given to shrink the tumor. This allows smaller doses of radiation to a smaller field and make the surgery technically more feasible. The European Organisation for Research and Treatment of Cancer (EORTC) is currently conducting a randomized trial comparing 50.4 Gy (Gray-unit to measure radiation therapy) of pre-operative radiation therapy with short-course radiotherapy, followed by surgery to direct surgery alone. Thus, continuous researches that are being conducted for the development of treatment for this disease is expected to create lucrative opportunities in the retroperitoneal liposarcoma treatment market during the forecast period.

Retroperitoneal Liposarcoma Treatment Market – Drivers

The global retroperitoneal liposarcoma treatment market is expected to exhibit a moderate growth rate, owing to low incidence of this disease across the globe. According to the World Health Organization (WHO) 2016, liposarcoma is the most common type of sarcomas (cancer of soft tissue) and is classified as a rare disease, which accounts for around 17-20% of all the cases (2.5 per Mn population) of sarcoma. Furthermore, rising incidence of genetic disorders is one of the major factors responsible for the global retroperitoneal liposarcoma treatment market growth. According to a report published by the Genetics Education Center, University of Kansas Medical Center, around 15% of all the cancers have an inherited susceptibility and around 12% of the hospital admissions in the U.S. accounted for the treatment of genetic causes in 2013. Various other factors contributing to market growth include changing lifestyle and growing awareness among populace regarding availability of treatment for liposarcoma through initiatives undertaken by various organizations. For instance, Liposarcoma Genome Project initiative by Massachusetts General Hospital Cancer Center conducted research to understand the differences between well-differentiated and de-differentiated liposarcoma, to support the development of treatment for the rare disease. However, high costs associated with the treatment procedures and low accessibility of the treatment due to rareness of the disease are expected to be factors hindering the market growth.

Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1861

Retroperitoneal Liposarcoma Treatment Market - Regional Analysis

On the basis of region, the global retroperitoneal liposarcoma treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds the maximum share for retroperitoneal liposarcoma treatment, owing to increasing research and development of novel therapies and potential drugs for dedifferentiated liposarcoma. For instance, the Sarcoma Foundation of America (SFA) aids sarcoma patients by providing funding for research to private researchers and conducts education campaigns for patients suffering from various types of sarcomas. Furthermore, Asia pacific also generates the significant value in retroperitoneal liposarcoma treatment market, owing to the presence of significant population suffering from the disease in this region. For instance, according to the Journal of Blood & Lymph 2013, in India around 35% of the patients suffering from sarcoma died due to dedifferentiated liposarcoma.

Retroperitoneal liposarcoma Treatment Market – Competitor Landscape

Increasing regulatory approvals by the U.S. FDA for various products manufactured by large companies is expected to boost the overall growth of the retroperitoneal liposarcoma treatment market. For instance, in 2015, the U.S. FDA granted priority review for the New Drug Application (NDA) for YONDELIS (trabectedin), manufactured by Janssen Research & Development, LLC to treat patients with advanced soft tissue sarcoma (STS), which includes liposarcoma and leiomyosarcoma subtypes in 77 countries, within North America, Europe, South America, and Asia. Furthermore, in 2016, Eisai Co., Ltd. received the approval in Japan for its in-house developed anticancer agent Halaven (eribulin mesylate) for the treatment of patients suffering from soft tissue sarcoma.

Market players operating in the global retroperitoneal liposarcoma treatment market include Eli Lilly and Company, Baxter International, Bristol Laboratories Ltd., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Actavis plc, Fresenius Kabi Ltd., Accord Healthcare Inc., Taro Pharmaceuticals Inc., Sandoz, Bedford Laboratories, and Zydus Cadila.

Ask for customization: https://www.coherentmarketinsights.com/insight/request-customization/1861

Retroperitoneal liposarcoma Treatment Market Taxonomy

The global retroperitoneal liposarcoma treatment market is segmented on the basis of chemotherapy treatment, type, distribution channel, and region.

By Chemotherapy Treatment:

Ifosfamide
Gemcitabine
Yondelis
Combinational Therapies
Other Chemotherapies
By Type:

Liposarcoma
Well-Differentiated Liposarcoma
Dedifferentiated Liposarcoma
Others
Leiomyosarcoma

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154
#3200

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Retroperitoneal Liposarcoma Treatment Market - Size, Share, Outlook, and Opportunity Analysis here

News-ID: 1206507 • Views: 214

More Releases from Coherent Market Insights

Sheet Face Masks Market - As Companies Committed for Digital Transformation, the …
Coherent Market Insights has released a new research study on the "Sheet Face Masks Market," which aims to provide a thorough examination of the factors influencing global business introduction and outlook. The Global Sheet Face Masks Market Report's detailed information and overview highlight the most recent trends in various regions. Leading market participants will benefit from the trading insights provided in this report. The Sheet Face Masks market research report
Lipid Testing Market Insights: 2022, Growing Business Demand and Upcoming Opport …
Coherent Market Insights has released a new research study on the "Lipid Testing Market," which aims to provide a thorough examination of the factors influencing global business introduction and outlook. The Global Lipid Testing Market Report's detailed information and overview highlight the most recent trends in various regions. Leading market participants will benefit from the trading insights provided in this report. The Lipid Testing market research report is an intelligence
After-sun Products Market - As Companies Committed for Digital Transformation, t …
Coherent Market Insights has released a new research study on the "After-sun Products Market," which aims to provide a thorough examination of the factors influencing global business introduction and outlook. The Global After-sun Products Market Report's detailed information and overview highlight the most recent trends in various regions. Leading market participants will benefit from the trading insights provided in this report. The After-sun Products market research report is an intelligence
Online Retail Market Will Generate Massive Growth 2022-2028 |Amazon Inc., Alibab …
Coherent Market Insights has released a new research study on the "Online Retail Market," which aims to provide a thorough examination of the factors influencing global business introduction and outlook. The Global Online Retail Market Report's detailed information and overview highlight the most recent trends in various regions. Leading market participants will benefit from the trading insights provided in this report. The Online Retail market research report is an intelligence

All 5 Releases


More Releases for Retroperitoneal

Retroperitoneal Liposarcoma Treatment Market Predicts Rise In Demand By 2026 | E …
Retroperitoneal liposarcoma (RLS) is a rare, biologically heterogeneous cancer, which occurs in retroperitoneum, lining of the abdominal space that covers the abdominal organs. Retroperitoneal liposarcoma grow continuously and may not get diagnosed until they are very large thus, its prognosis is poor compared to the other subtypes of retroperitoneal sarcomas. The reason for the development of these tumors are still unknown, however, genetic mutation is considered to be one of
Retroperitoneal Liposarcoma Treatment Market Clinical Review, Drug Descriptions, …
Retroperitoneal liposarcoma (RLS) is a rare, biologically heterogeneous cancer, which occurs in retroperitoneum, lining of the abdominal space that covers the abdominal organs. Retroperitoneal liposarcoma grow continuously and may not get diagnosed until they are very large thus, its prognosis is poor compared to the other subtypes of retroperitoneal sarcomas. The reason for the development of these tumors are still unknown, however, genetic mutation is considered to be one of
Retroperitoneal Fibrosis Treatment Market Forecast and Segments, 2018-2028
Retroperitoneal fibrosis is the rare disease also known as Ormond’s disease. Retroperitoneal fibrosis is characterized by the inflammatory disorder in which abnormal formation of tissue or fibrosis occurs in the back of the abdominal cavity and behind the retro membrane. This area is known as retroperitoneal space. The abnormal tissue growth affects the urinary tubes of the kidney. Often these tubes are blocked by fibrosis. According to the National Institute
Global Retroperitoneal Fibrosis Treatment Market Future Outlook and Trends Indic …
Retroperitoneal fibrosis is the rare disease also known as Ormond’s disease. Retroperitoneal fibrosis is characterized by the inflammatory disorder in which abnormal formation of tissue or fibrosis occurs in the back of the abdominal cavity and behind the retro membrane. This area is known as retroperitoneal space. The abnormal tissue growth affects the urinary tubes of the kidney. Often these tubes are blocked by fibrosis. According to the National Institute
Retroperitoneal Liposarcoma Treatment Market - Size, Share, Outlook, and Opportu …
Retroperitoneal liposarcoma (RLS) is a rare, biologically heterogeneous cancer, which occurs in retroperitoneum, lining of the abdominal space that covers the abdominal organs. Retroperitoneal liposarcoma grow continuously and may not get diagnosed until they are very large thus, its prognosis is poor compared to the other subtypes of retroperitoneal sarcomas. The reason for the development of these tumors are still unknown, however, genetic mutation is considered to be one of
Retroperitoneal Liposarcoma Treatment Market - Size, Outlook, and Opportunity An …
Retroperitoneal liposarcoma (RLS) is a rare, biologically heterogeneous cancer, which occurs in retroperitoneum, lining of the abdominal space that covers the abdominal organs. Retroperitoneal liposarcoma grow continuously and may not get diagnosed until they are very large thus, its prognosis is poor compared to the other subtypes of retroperitoneal sarcomas. The reason for the development of these tumors are still unknown, however, genetic mutation is considered to be one of